Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by:
University of Mississippi Medical Center
ClinicalTrials.gov Identifier:
NCT00691873
First received: June 3, 2008
Last updated: June 5, 2008
Last verified: January 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2007
  Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)